A 2003 letter by Parisi and colleagues (the Italian AISGE group) reported that none of 85 consecutive irritable bowel syndrome (IBS) patients tested positive for small intestinal bacterial overgrowth (SIBO) on glucose hydrogen breath testing, challenging Pimentel's lactulose-based reports of 78–84% positivity and questioning whether IBS warrants long-term antibiotic therapy at all. The letter left open whether larger cohorts would detect SIBO in a subset of IBS patients, called for research to resolve the SIBO–IBS relationship, and flagged the long-term effects of antibiotics on intestinal bacteria and on the development of functional bowel symptoms. Later literature resolved the letter's narrow null hypothesis against it — meta-analyses of larger studies find breath-test-positive SIBO in roughly one-third of IBS patients (pooled odds ratios ~2.6–5.7 versus controls) — but culture-based estimates are lower (roughly 4–19%), and the deeper question remains open: the true prevalence of SIBO in IBS by valid diagnostics, the causal and clinical significance of the association, and the long-term microbiome consequences of SIBO-directed antibiotic therapy are all still contested, with the most recent literature (2024–2026) still framing the question as active.

Background

Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction — a diagnosis made by symptom-based criteria (the Rome criteria: recurrent abdominal pain related to defecation, accompanied by altered stool form or frequency, with no detectable structural lesion) once organic disease has been excluded. It affects roughly 4–11% of adults and is among the most frequent diagnoses in gastroenterology clinics. Small intestinal bacterial overgrowth (SIBO) denotes an abnormally heavy bacterial population in the small intestine, classically defined by culture of a jejunal aspirate (fluid drawn from the upper small bowel during endoscopy) yielding at least 10510^5 colony-forming units per milliliter. SIBO produces bloating, flatulence, diarrhea, and abdominal discomfort — symptoms that overlap almost completely with IBS — and is treated with antibiotics.

Because jejunal aspiration is invasive, SIBO is usually screened with carbohydrate breath tests: the patient ingests a substrate (glucose or lactulose) and exhaled breath hydrogen (and methane) is sampled over 2–3 hours; a rise indicates bacterial fermentation in the small intestine before the substrate reaches the colon. Accuracy against jejunal culture is imperfect and substrate-dependent: the glucose breath test (GBT) was reported to have about 93% sensitivity and 78% specificity (Kerlin & Wong, 1988), whereas the lactulose hydrogen breath test (LHBT) performed poorly (sensitivity about 17%; Riordan et al., 1996), because lactulose is also fermented by normal cecal bacteria, so early breath rises often reflect rapid intestinal transit rather than overgrowth.

Against this background, Pimentel, Chow, and Lin reported in 2000 that 78% of 202 IBS patients had SIBO by LHBT and that IBS symptoms improved after eradication, and in 2003 that 84% of IBS subjects had abnormal lactulose breath tests versus 20% of healthy controls, with symptom improvement tracking breath-test normalization under neomycin — collectively suggesting a causal microbial contribution to IBS. In a 2003 letter to the editor, Parisi and colleagues (an Italian multicenter group, AISGE) countered with preliminary data from 85 consecutive Rome II IBS patients recruited from six Italian gastroenterology clinics: using a 50-g GBT with a hydrogen-increment positivity criterion of ≥10 ppm, no patient (0%) tested positive. They attributed the discrepancy to the poor validity of the LHBT and cautioned that IBS is a long-term condition, that antibiotic treatment might be detrimental to intestinal bacteria, and that antibiotics might themselves influence the development of functional bowel syndromes. The letter's own hedge — that the limited sample left open whether larger studies would detect SIBO in a subset of IBS patients — framed the question the field then spent two decades addressing: what, in fact, is the relationship between SIBO and IBS?

Problem Statement

Determine the relationship between small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS), as the source letter framed it. The question has three dimensions:

  1. True prevalence with valid diagnostics: in adequately powered cohorts of IBS patients and controls, establish whether SIBO is genuinely present in a subset of IBS patients and at what true prevalence, using diagnostics whose validity is established against jejunal or duodenal aspirate culture as reference, so as to settle the method dependence between breath-test-based (roughly 30–40%) and culture-based (roughly 4–19%) estimates.

  2. Causal and clinical significance: establish whether SIBO contributes causally to IBS symptoms — as opposed to being a consequence of IBS physiology (altered transit, secretion, or diet) or an artifact of imperfect tests — including whether eradicating SIBO in test-positive IBS patients durably improves symptoms beyond placebo.

  3. Long-term antibiotic effects: characterize the long-term consequences of SIBO-directed antibiotic therapy for the intestinal microbiota of IBS patients, and determine whether such antibiotic exposure itself promotes the development of functional bowel symptoms.

These three dimensions are aspects of the single question the letter posed — whether a microbial overgrowth component is a real, diagnosable, and treatable contributor to IBS. All three are in scope: the task is resolved by a defensible synthesis-of-evidence verdict on each, grounded in the cited literature and the current state of the field, and does not require new primary data. (The original narrow form of dimension 1, confirming the absence of SIBO in IBS by glucose breath test, together with the narrow sub-question of whether larger cohorts would detect SIBO in a subset of IBS patients, has been resolved against the letter's null finding by later larger studies and is not part of what remains.)

References

  1. Parisi G, Leandro G, Bottona E, Carrara M, Cardin F, Faedo A, Goldin D, Pantalena M, Tafner G, Verdianelli G, Zilli M; AISGE Group. Small intestinal bacterial overgrowth and irritable bowel syndrome (letter). Am J Gastroenterol 2003;98(11):2572, author reply 2573-4. DOI: 10.1016/s0002-9270(03)01719-2. https://doi.org/10.1016/s0002-9270(03)01719-2
  2. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95(12):3503-6. DOI: 10.1111/j.1572-0241.2000.03368.x. https://doi.org/10.1111/j.1572-0241.2000.03368.x
  3. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98(2):412-9. DOI: 10.1111/j.1572-0241.2003.07234.x. https://doi.org/10.1111/j.1572-0241.2003.07234.x
  4. Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology 1988;95(4):982-8. DOI: 10.1016/0016-5085(88)90173-4. https://doi.org/10.1016/0016-5085(88)90173-4
  5. Riordan SM, McIver CJ, Walker BM, Duncombe VM, Bolin TD, Thomas MC. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 1996;91(9):1795-803. PMID: 8792701. https://pubmed.ncbi.nlm.nih.gov/8792701/
  6. Riordan SM, Kim R. Bacterial overgrowth as a cause of irritable bowel syndrome. Curr Opin Gastroenterol 2006;22(6):669-73. DOI: 10.1097/01.mog.0000245544.80160.46. https://doi.org/10.1097/01.mog.0000245544.80160.46
  7. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007;56(6):802-8. DOI: 10.1136/gut.2006.108712. https://doi.org/10.1136/gut.2006.108712
  8. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009;7(12):1279-86. DOI: 10.1016/j.cgh.2009.06.031. https://doi.org/10.1016/j.cgh.2009.06.031
  9. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364(1):22-32. DOI: 10.1056/NEJMoa1004409. https://doi.org/10.1056/NEJMoa1004409
  10. Chen B, Kim JJ, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol 2018;53(7):807-18. DOI: 10.1007/s00535-018-1476-9. https://doi.org/10.1007/s00535-018-1476-9
  11. Klem F, Wadhwa A, Prokop LJ, Sundt WJ, Farrugia G, Camilleri M, Singh S, Grover M. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology 2017;152(5):1042-1054.e1. DOI: 10.1053/j.gastro.2016.12.039. https://doi.org/10.1053/j.gastro.2016.12.039
  12. Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, Paterson C, Bortey E, Forbes WP. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 2016;151(6):1113-21. DOI: 10.1053/j.gastro.2016.08.003. https://doi.org/10.1053/j.gastro.2016.08.003
  13. Pimentel M, Cash BD, Lembo A, Wolf RA, Israel RJ, Schoenfeld P. Repeat rifaximin for irritable bowel syndrome: no clinically significant changes in stool microbial antibiotic sensitivity. Dig Dis Sci 2017;62(9):2455-63. DOI: 10.1007/s10620-017-4598-7. https://doi.org/10.1007/s10620-017-4598-7
  14. Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol 2017;112(5):775-84. DOI: 10.1038/ajg.2017.46. https://doi.org/10.1038/ajg.2017.46
  15. Shah A, Talley NJ, Jones M, Kendall BJ, Koloski N, Walker MM, Morrison M, Holtmann GJ. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol 2020;115(2):190-201. DOI: 10.14309/ajg.0000000000000504. https://doi.org/10.14309/ajg.0000000000000504
  16. Ghoshal UC, Nehra A, Mathur A, Rai S. A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome. J Gastroenterol Hepatol 2020;35(6):922-31. DOI: 10.1111/jgh.14938. https://doi.org/10.1111/jgh.14938
  17. Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol 2021;116(1):17-44. DOI: 10.14309/ajg.0000000000001036. https://doi.org/10.14309/ajg.0000000000001036
  18. Takakura W, Rezaie A, Chey WD, Wang J, Pimentel M. Symptomatic response to antibiotics in patients with small intestinal bacterial overgrowth: a systematic review and meta-analysis. J Neurogastroenterol Motil 2024;30(1):7-16. DOI: 10.5056/jnm22187. https://doi.org/10.5056/jnm22187
  19. Colecchia L, Marasco G, Capelli C, Facciorusso A, Maida MF, Vitello A, Dajti E, Barbaro MR, Gobbato A, Cremon C, Barbara G. Antibiotic use during gastrointestinal infections increases the risk of developing irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2026 (published online March 20, 2026). DOI: 10.14309/ajg.0000000000004001. https://doi.org/10.14309/ajg.0000000000004001
  20. Lu H. Relationship between small intestinal bacterial overgrowth and irritable bowel syndrome and the efficacy of rifaximin intervention: a systematic review and meta-analysis. Front Microbiol 2026;17:1780567. DOI: 10.3389/fmicb.2026.1780567. https://doi.org/10.3389/fmicb.2026.1780567